Health Economics›Esophageal cancer›Neoadjuvant induction therapy

Neoadjuvant induction therapy

Esophageal cancer · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
FLEP Variant #01	—	R 3 856	21d	—	—	—	—	—
EOX Variant #01	—	R 3 411	21d	—	~11.3 mo	—	—	1
EOF Variant #01	—	R 3 063	21d	—	~48.0 mo	—	—	1
Cisplatin and Fluorouracil (CF) Variant #29	—	R 1 900	21d	—	14.9 mo	—	—	2
Capecitabine and Cisplatin (CX) Variant #01	—	R 1 386	21d	~5.5 mo	~10.9 mo	~8	~R 11 092 PFS proxy · indirect	10
Cisplatin and Irinotecan (IC) N/A - secondary systemic drug	—	R 743	42d	~3.8 mo	~13.9 mo	~3	~R 2 230 PFS proxy · indirect	2
PCF N/A - secondary systemic drug	—	R 604	21d	—	—	—	—	—
Cisplatin and Docetaxel (DC) N/A - secondary systemic drug	—	R 449	21d	24.0 mo	—	35	R 15 722 PFS proxy	1
No neoadjuvant therapy Partial	—	—	—	—	—	—	—	2

9 of 9 regimens shown